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Edited by Judit Ova´diAbstract Peptidyglycine a-amidating monooxygenase is a cop-
per- and zinc-dependent, bifunctional enzyme that catalyzes the
cleavage of glycine-extended peptides or N-acylglycines to the
corresponding amides and glyoxylate. This reaction is a key
step in the biosynthesis of bioactive a-amidated peptides and,
perhaps, the primary fatty acids amides also. Two clinically use-
ful N-acylglycines are thiorphan and tiopronin, each with a thiol
moiety attached to the acyl group. We report here that thiorphan
and tiopronin are substrates for PAM, exhibiting relatively low
KM,app and VMAX,app values. The low VMAX,app values result,
most likely, from a decrease in active PAM Æ 2Cu(II) as the
enzyme competes ineﬀectively with thiorphan and tiopronin for
free copper.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Thiorphan (N-[(R,S)-3-mercapto-2-benzylpropionyl]glycine)
and tiopronin (N-(2-mercaptopropionyl)glycine) or N-(2-mer-
capto-1-oxopropyl)glycine, also known as thiola are two thiol
containing drugs. Thiorphan, administered as the prodrug
racecadotril (also called acetorphan), is a low nanomolar
inhibitor of neutral endopeptidase (NEP or enkephalinase,
EC, 3.4.24.11) [1] and is used as an antidiarrheal [2,3]. Tiopro-
nin is a metal chelator and antioxidant used to treat cystinuria
[4], mercury and copper poisoning [5,6], and rheumatoid
arthritis [7]. In addition, tiopronin is cytoprotective during
myocardial ischemia and reperfusion [8,9] and may ﬁnd use
as a nephroprotective agent for the toxicity associated with
cisplatin treatment [10].
Both thiorphan and tiopronin are N-substituted glycines
(Fig. 1). Work from our laboratory [11–14] and from the
May group [15] has shown that N-substituted glycines, the
N-acyl- and N-arylglycines, are substrates for peptidylglycine
a-amidating monooxygenase (PAM, EC 1.14.17.3). PAM cat-
alyzes the ﬁnal reaction in a-amidated peptide biosynthesis
[16,17] and recent evidence suggests that the enzyme may also
have a role in the biosynthesis of oleamide and other fatty acid
primary amides [18,19]. PAM is a bifunctional enzyme consist-*Corresponding author. Fax: +1 813 974 1733.
E-mail address: merkler@mail.cas.usf.edu (D.J. Merkler).
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monooxygenase (PHM) catalyzes the copper-, O2-, and ascor-
bate-dependent hydroxylation of the terminal glycyl a-carbon
while peptidylamidoglycolate lyase (PAL) catalyzes the zinc-
dependent dealkylation of the a-hydroxylglycine intermediate
to the amide product and glyoxylate (Fig. 2) [20,21].
We report here that thiorphan, tiopronin, and number of
structurally related analogs are substrates or inhibitors of
PAM. Both thiophan and tiopronin bind to PAM with Kd val-
ues 6100 lM, yet show low rates of amidation. The Kd values
for thiorphan and tiopronin are equal to or lower than the
KM,app values for the glycine-extended peptide substrates for
PAM, which is surprising for such small, simple compounds.
Generally, small structurally simple PAM substrates like
N-benzoylglycine and short-chain N-acylglycines exhibit
KM,app values >1.0 mM. Modeling studies indicate that the
relatively strong aﬃnity of tiopronin and thiorphan for PAM
is a result of their interaction with copper and that the low
rates of amidation observed for these compounds, most likely,
results from a decrease in the PAM Æ 2Cu(II) concentration.
PAM requires two bound copper atoms for maximum activity.
This study provides new insights not only about the pharmaco-
logical activity of thiorphan and tiopronin, but also into the
development of novel drugs targeted against PAM.2. Materials and methods
2.1. Materials
a-Hydroxyhippuric acid, a-methylhydrocinnamic acid, isobutyric
anhydride, and oxalyl chloride were from Aldrich, tiopronin, S-pro-
pylglutathione, and N-acetylglycine were from Sigma, thiorphan was
from Bachem, N-dansyl-Tyr-Val-Gly was from Fluka BioChemika,
and bovine catalase was from Worthington. Recombinant rat PAM
was gift from Unigene Laboratories, Inc. All other reagents were of
the highest quality available from commercial suppliers.
2.2. Synthesis
N-[(R,S)-2-Methylhydrocinnamoyl]glycine, N-[(R,S)-2-ethylhydro-
cinnamoyl]glycine, N-isobutyrylglycine, and S-methyltiopronin were
prepared by conventional procedures and authenticated by elemental
analysis (Atlantic Microlab Inc.) and 1H NMR (Inova 400 spectropho-
tometer), CDCl3–DMSO-d6 (95:5) or D2O, chemical shifts ppm (d)
relative to TMS or DSS. Full experimental details are provided below.
2.2.1. S-Methyltiopronin (N-(2-methylsulfanyl-1-oxopropyl)gly-
cine). A solution of tiopronin (0.8 gm, 4.9 mmol) and sodium car-
bonate (0.6 gm, 5.7 mmol) in water (6 mL) was stirred with methyl
iodide (0.8 gm, 5.6 mmol) until the organic layer disappeared and car-
bon dioxide evolution ceased (60 min), then acidiﬁed (3 M HCl, 4 mL)
and extracted repeatedly with diethyl ether. Crude product (0.65 gm,
75%) recrystallized from ethyl acetate m.p. 109–110 C [Ref. [22],
112–113 C]. 1H NMR (D2O): d 1.26 (d, J = 7 Hz, 3H), 1.99 (s, 3H),
3.37 (q, J = 7 Hz, 1H) 3.87 (s, 2H).ation of European Biochemical Societies.
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Fig. 2. The reaction catalyzed by bifunctional PAM. PAM is a comprised of two distinct catalytic entities: peptidyl a-hydroxylating monooxygenase
(PHM) and peptidylamidoglycolate lyase (PAL).
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Fig. 1. Thiorphan and tiopronin structures. The arrows indicate the bond cleaved by PAM.
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glycine). a-Ethylcinnamic acid [23] (3.5 gm, 20 mmol) in aqueous
sodium hydroxide (22 mL 1 M) was stirred three days with sodium
amalgam (sodium, 1.35 gm, 60 mg-at, in mercury, 100 gm). The ﬁltered
aqueous phase was acidiﬁed and extracted with dichloromethane to
give a-ethylhydrocinnamic acid (3.5 gm, quantitative) as an oil, shown
by NMR to be free from unsaturated precursor. This acid (2.6 gm,
15 mmol) reacted with oxalyl chloride (5.6 gm, 45 mmol) for 1 h at
25 C then 15 min at 60 C. The solvent was then stripped of volatiles
and the resulting acid chloride was stirred overnight with a solution of
glycine (1.7 gm, 23 mmol) and sodium carbonate (4.8 gm, 45 mmol) in
water (30 mL). Acidiﬁcation gave a precipitate of the target N-acylgly-
cine. Recrystallized from diethyl ether (100 mL), 2.29 gm, 65%, m.p.
107–109 C. 1H NMR (CDCl3): d 0.85 (t, J = 7 Hz, 3H), 1.41–1.50
(m, 1H), 1.56–1.65 (m, 1H), 2.23–2.30 (m, 1H), 2.64 (dd, J1 = 6.5
J2 = 13.5 Hz, 1H), 2.87 (dd, J1 = 8.5 J2 = 13 Hz, 1H), 3.75 (dd,
J1 = 4.5 J2 = 19 Hz,1H), 3.95 (dd, J1 = 5 J2 = 19 Hz, 1H), 6.16 (s,
1H), 7.01–7.20 (m, 5H).
2.2.3. N-[(R,S)-2-Methylhydrocinnamoyl]glycine (N-(2-benzylpro-
pionyl)glycine). a-Methylhydrocinnamic acid (1.64 gm, 10 mmol)
reacted with oxalyl chloride (2.5 gm, 20 mmol) for 1 h at 25 C then
15 min at 60 C. The solvent was stripped of volatiles and the resulting
acid chloride stirred overnight with a solution of glycine (1.5 gm,
20 mmol) and sodium carbonate (4.1 gm, 40 mmol) in water (40 mL).
Acidiﬁcation gave a crystalline precipitate of the target N-acylglycine
(1.55 gm, 70%). Recrystallized from diethyl ether (50 mL) mp 113–
114 C. 1H NMR (CDCl3): d 1.65 (d, J = 7 Hz, 3H), 2.51–2.68 (m,
2H), 3.01 (dd, J1 = 7 J2 = 14 Hz, 1H), 3.87(dd, J1 = 4.5 J2 = 18.5 Hz,
1H), 4.01 (dd, J1 = 4.5 J2 = 18.5 Hz, 1H), 6.20 (br.s, 1H), 7.15–7.29
(m, 5H).
2.2.4. N-Isobutyrylglycine (3-aza-4-oxo-5-methylhexanoic acid).
Isobutyric anhydride (32 gm, 200 mmol) was added in one portion to a
stirred mixture of glycine (7.5 gm, 100 mmol) and water (30 mL). The
mixture was heated, eventually to boiling, then stripped of volatiles
under reduced pressure to give a waxy solid which was extracted
with 10 successive portions of boiling diethyl ether. Partial evaporation
of the extracts gave the crystalline acylglycine (6.3 gm, 45%) m.p. 104–
106 C. 1H NMR (CDCl3): d 1.17 (d, J = 7 Hz, 6H), 2.41–2.51 (m, 1H),
3.99 (s, 2H), 6.54 (br.s, 1H).
2.3. Molecular modeling
Glide (grid-based ligand docking with energetics) from the FirstDis-
covery 3.0 suite (www.schrodinger.com) was used for substrate analysis
[24,25]. The coordinates of oxidized and reduced peptidylglycine
a-hydroxylating monooxygenase (PHM) were obtained from theProtein Data Bank [26,27]. The enzyme-bound coppers, CuM and
CuH, were selected within atom type parameters to be Cu(I) for reduced
and Cu(II) for oxidized PHM grids.
Several protein grids were prepared: reduced PHM Æ 2Cu(I) with
bound O2, reduced PHM Æ 2Cu(I) with no bound O2, and oxidized
PHM Æ 2Cu(II). Prior to determination of the grid enclosure, species
determined to be redundant for ligand binding were removed (nickel,
water, glycerol and co-crystallized substrate). With no further energy
minimizations of the co- crystallized protein structure, ProteinPrep
was used to add hydrogens and perform a restrained minimization.
The bounding box containing all ligand atoms was increased from
10 A˚3 (default) to 14 A˚3. This was done to ensure all residues surround-
ing both PHM copper binding sites were included within the enclosing
box. Substrates underwent energy minimization in Chem3D Ultra 8.0
with MM2 and were then imported into Maestro. Standard Precision
mode was used for ligand docking investigation with 30–50 poses
per ligand. The top pose for each ligand was selected based on the cor-
relation of Emodel and Glide score, respectively. Positive controls were
completed for each experiment through re-docking of the co-crystal-
lized substrate.
2.4. Determination of KM,app and VMAX,app values for N-[(R,S)-2-
methylhydrocinnamoyl]glycine, N-[(R,S)-2-ethylhydro-
cinnamoyl]glycine, L-alanylglycine, N-(isobutyryl)glycine, and
S-methyltiopronin
Reactions at 37.0 ± 0.1 C were initiated by the addition of PAM
(30–70 lg) into 2.0–3.0 mL of 100 mM MES/NaOH pH 6.0, 30 mM
NaCl, 1% (v/v) ethanol, 0.001% (v/v) Triton X-100, 1.0 lM Cu(NO3)2,
5.0 mM sodium ascorbate, and the oxidizable substrate (generally 0.3–
5.0 KM,app). Initial rates were measured by following the PAM-depen-
dent consumption of O2 using a Yellow Springs Instrument Model 53
oxygen monitor interfaced with a personal computer using a Dataq
Instruments analogue/digital converter (model DI-154RS). VMAX,app
values were normalized to controls performed at 11.0 mM N-acetylgly-
cine. Ethanol was added to protect the catalase against ascorbate-
mediated inactivation and Triton X-100 was included to prevent
non-speciﬁc absorption of PAM to the sides of the oxygen monitor
chambers.
2.5. Inhibition of O2 consumption from N-acetylglycine by tiopronin
Reactions at 37.0 ± 0.1 C were initiated by the addition of PAM
(36 lg) into 2.5 mL of 100 mM MES/NaOH, pH 6.0, 30 mM NaCl,
5.0 mM sodium ascorbate, 1.0% (v/v) ethanol, 0.001% (v/v) Triton
X-100, 10 lg/ml bovine catalase, 1.0 lM Cu(NO3)2, 2.5–20 mM
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by following the PAM-dependent consumption of O2 using the previ-
ously mentioned oxygen monitor apparatus.2.6. Inhibition of N-dansyl-Tyr-Val-Gly amidation by thiorphan and
S-methyltiopronin
Reactions at 37.0 ± 0.1 C were initiated by the addition of PAM
(45–50 ng) into 500 lL of 100 mMMES/NaOH, pH 6.0, 30 mMNaCl,
5.0 mM sodium ascorbate, 1.0% (v/v) ethanol, 0.001% (v/v) Triton
X-100, 10 lg/ml bovine catalase, 1.0 lM Cu(NO3)2, 1.25–20 lM
N-dansyl-Try-Val-Gly, and 0–120 lM thiorphan or 0–2500 lM
S-methyltiopronin. At the desired time, an aliquot was removed and
added to a vial containing one-ﬁfth volume of 6% (v/v) triﬂuoroacetic
acid to terminate the reaction. The acidiﬁed aliquots were assayed for
the percent conversion to N-dansyl-Try-Val–NH2 by reverse phase
HPLC as described by Jones et al. [28].2.7. Glyoxylate production from thiorphan, tiopronin, and
a-hydroxyhippuric acid
To ﬁrst determine if thiorphan and tiopronin were amidated by
PAM, 36 lg of PAM was added to 1.2 mL of 100 mM MES/NaOH,
pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Trition
X-100, 10 lg/mL catalase, 1.0 lM Cu(NO3)2, 5.0 mM sodium ascor-
bate, and either 200 lM thiorphan or 200 lM tiopronin. After a 3 h
incubation at 37 C, the reaction was terminated by the addition
300 lL of 6% (v/v) TFA and duplicate 100 lL aliquots were removed
for glyoxylate analysis.
Initial rates of glyoxylate formation from thiorphan and tiopronin
were determined by adding 30 lg of PAM to a 3.0 mL solution con-
taining 100 mM MES/NaOH, pH 6.0, 30 mM NaCl, 1.0% (v/v) etha-
nol, 0.001% (v/v) Trition X-100, 10 lg/mL catalase, 1.0 lM
Cu(NO3)2, 1.8 mM sodium ascorbate, and either 83 lM thiorphan or
83 lM tiopronin. At 5 min intervals from 5 to 25 min., a 500 lL ali-
quot was removed, added to a vial containing 100 lL of 6% (v/v)
TFA to terminate the reaction, and the concentration of glyoxylate
formed measured in the acidiﬁed samples.
Initial rates of glyoxylate formation from a-hydroxyhippurate as a
function of the thiorphan concentration were determined by adding
10 lg of PAM to a 850 lL solution containing 100 mM MES/NaOH,
pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001% (v/v) Trition X-100,
2.0 mM a-hydroxyhippurate, and 0–6.0 mM thiorphan. At 5 min
intervals from 5 to 25 min, a 150 lL aliquot was removed, added
to a vial containing 30 lL of 6% (v/v) TFA to terminate the reaction,
and the concentration of glyoxylate formed measured in the acidiﬁed
samples.
Glyoxylate was determined by the spectrophotometric method of
Christman et al. [29] as modiﬁed by Katopodis and May [15]. Stan-
dard curves of [glyoxylate] vs. A520 were constructed in the appropri-
ate buﬀers using a glyoxylate solution that had been calibrated by
measuring the glyoxylate-dependent oxidation of NADH (De340 =
6.22 · 103 M1 cm1) as catalyzed by lactate dehydrogenase.1 Ascorbate is a PAM substrate being oxidized to the ascorbate
radical, semidehydroascorbate, during catalysis. The substrate being
referred to here is the N-substituted glycine substrate that is ultimately
converted to the amide and glyoxylate.2.8. Analysis of steady-state kinetic data
Steady-state kinetic parameters (±S.E.) were obtained by a Kaleida-
Graphe ﬁt of the initial velocity (v) vs. substrate concentration, ([S]),
data to
v ¼ ðV MAX;app½SÞ=ðKM;app þ ½SÞ ð1Þ
where KM,app is the apparent Michaelis constant for the oxidizable sub-
strate at ﬁxed [ascorbate] and [O2] concentrations and VMAX,app is the
apparent maximum initial velocity at saturating [oxidizable substrate].
Initial rate studies that resulted in competitive inhibition were ana-
lyzed by a SigmaPlot 8.0e ﬁt of the v vs. [S] data as a function of
the inhibitor concentration to Eq. (2). Initial rate studies that resulted
in mixed, inhibition were analyzed by a SigmaPlot 8.0e ﬁt of the v vs.
[S] data as a function of the inhibitor concentration to Eq. (3).
v ¼ ðV MAX;app½AÞ=½KM;appð1þ ½I =K i;sÞ þ ½A ð2Þ
v ¼ ðV MAX;app½AÞ=½KM;appð1þ ½I =K i;sÞ þ ½Að1þ ½I=K i;iÞ ð3Þ
The IC50 value for the inhibition of a-hydroxyhippurate dealkylation
by thiorphan was obtained by analysis of the initial velocity, v, vs. [thi-
orphan] data as described by Corte´s et al. [30].3. Results and discussion
3.1. Thiorphan and tiopronin as PAM substrates and inhibitors
We routinely monitor PAM catalysis using three methods: (a)
the substrate-dependent consumption of O2, (b) the substrate-
dependent production of glyoxylate, and (c) the conversion of
N-dansyl-Tyr-Val-Gly to either N-dansyl-Tyr-Val-a-hydroxy-
glycine orN-dansyl-Tyr-Val–NH2 (Fig. 2). Of these three meth-
ods, O2 consumption is the least sensitive and, thus, is the most
diﬃcult to use when employing substrates with a low VMAX.
1
Attempts to measure O2 consumption using either thiorphan
or tiopronin as an oxidizable substrate were unsuccessful, a
typical result being shown in Fig. 3. The inhibition of O2 con-
sumption from N-acetylglycine by thiorphan (Fig. 3) indicated
that this N-substituted glycine did bind to PAM, but that it was
either a substrate with a low VMAX or an inhibitor. Incubation
of 30 lg/ml PAM with either 200 lM thiorphan or 200 lM
tiopronin for 3 h at 37 C yielded glyoxylate from both com-
pounds, 64 ± 7 lM glyoxylate from thiorphan and 43 ± 5 lM
glyoxylate from tiopronin. A control containing 200 lM S-pro-
pylglutathione, a known PAM substrate [31], generated
181 ± 1 lM glyoxylate. In each, the amount of glyoxylate pro-
duced is the average ±S.D. for duplicate samples. At 83 lM
substrate, we measured initial rates of glyoxylate production,
460 ± 8 nmol/min/mg for thiorphan and 84 ± 5 nmol/min/mg
for tiopronin. The production of glyoxylate from thiorphan
and tiopronin indicates that both are PAM substrates, but
exhibit low VMAX values relative to the glycine-extended pep-
tide and N-acylglycine substrates.
Because the VMAX,app values for thiorphan and tiopronin
are low, we analyzed their interaction with PAM by standard
steady-state inhibition. Both are mixed-type inhibitors vs. a
glycine-extended peptide substrate with kinetic constants of
Ki,s = 82 ± 11 lM and Ki,i = 120 ± 30 for thiorphan (data not
shown) and Ki = 33 ± 5.1 lM and Ki,i = 40 ± 10 for tiopronin
inhibition (Fig. 4A).
Thiorphan inhibits NEP and other zinc-dependent proteins
by binding to the protein-bound zinc [32]. As the PAL-cata-
lyzed dealkylation is zinc-dependent, thiorphan was tested as
a potential PAL inhibitor. PAL activity within bifunctional
PAM was measured through the formation of glyoxylate
from a-hydroxyhippurate, C6H5–CO—NH–CHOH–COOHﬁ
C6H5–CONH2 + OCH–COOH, in the absence of ascorbate.
Thiorphan was observed to weakly inhibit the PAL-dependent
dealkylation of a-hydroxyhippurate with an IC50 = 3.5 ±
0.53 mM.
3.2. Analogs of thiorphan and tiopronin as PAM substrates and
inhibitors
The aﬃnity exhibited by PAM for such simple N-substituted
glycines as thiorphan and tiopronin is surprising given the
available structure-activity data indicates that the substrates
with KM values <100 lM are larger, being either glycine-
extended peptides or long-chain N-acylglycines [11,15,33]. Our
hypothesis was that the thiol or thiolate moiety of thiorphan
and tiopronin is responsible for the unexpected results we have
obtained regarding the interaction of these molecules with
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genase (DbM), are both copper-dependent monooxygenases
with 2 bound copper atoms per active site [26,34–36]. The inhi-
bition of PAM by homocysteine-extended peptides [37] and by
captopril ((2S)-1-(3-mercapto-2-methylpropionyl)-L-proline)
[38] has been attributed to the interaction of a sulfur atom with
enzyme-bound copper. Similarly, inhibition of DbM by capto-
pril, cysteine, and glutathione has been ascribed to in situ che-
lation of the enzyme-bound coppers [39,40]. Consistent with
our hypothesis, we found that thiorphan and tiopronin ana-
logs lacking a thiol moiety bind to PAM with lower aﬃnity
(Table 1). Replacement of the thiol with a methyl in thiorphan
and tiopronin increases the KM,app  40-fold indicating that
the —SH moiety contributes approximately 2 kcal/mol in
binding energy relative to –CH3. S-Methyltiopronin was syn-
thesized to further address the eﬀect of the free-thiol (—SH)
moiety on binding aﬃnity. Unlike the mixed-type inhibition
displayed with tiopronin, S-2-methylthiopronin was observed
to be a competitive inhibitor vs. N-dansyl-Tyr-Val-Gly with
a Ki,s = 190 ± 14 lM (Fig. 4B).
2
3.3. The decrease in PAM Æ 2Cu(II) concentration by thiorphan
and tiopronin
PAM and DbM both contain two active site copper atoms
that undergo reversible oxidation/reduction during their
respective catalytic cycles [41,42]. Sulfur-containing ligands
bind strongly to Cu(II). Possible explanations for the results2 The KM value for a substrate should equal the Ki,s value for that
compound if it is employed as a competitive inhibitor against a
diﬀerent substrate [45]. The ratio of the KM,app/Ki,s,app for S-2-
methylthiopronin is 2.4 ± 0.41 and does not match the expected ratio
of 1.0. While not far out of agreement with the expected ratio, the
reason for the discrepancy is not currently understood.presented here, and other reports on the inhibition of PAM
and DbM by sulfur-containing ligands [37–40], is that the sul-
fur-containing ligands either chelate to active site copper, form-
ing an E-2Cu(II) Æ inhibitor complex, or remove the active site
copper, forming a copper-free-E and separate Cu(II) Æ inhibitor
complexes. The copper-free forms of PAM and DbM are inac-
tive [41,42]. Experimentally, it is diﬃcult to diﬀerentiate be-
tween these possibilities. One straightforward experiment
would be to measure the copper stoichiometry before and after
treatment with the sulfur-containing inhibitor. Unfortunately,
this approach will not work because PAM, as isolated, contains
no bound copper [34]. Another possible approach would be to
measure spectral changes upon the addition of the sulfur-con-
taining inhibitors to PAM. Such changes will show that the sul-
fur is coordinated to the copper, as has been demonstrated [43],
but are not likely to provide deﬁnitive proof that the
copper Æ inhibitor complex is enzyme-bound.
Table 1
Steady-state kinetic for thiorphan, tiopronin and respective analogsa,b
Compound KM,app (lM) VMAX,app (lmol/min/mg) (V/K)app (M
1sec1)
Thiorphan
C6H5 NH
COOH
SH
O
82 ± 11 1.2c 2 · 104
N-[(R,S)-2-Methylhydrocinnamoyl]glycine
C6H5 NH
COOH
O
4100 ± 310 6.4 ± 0.32 2.0 ± 0.18 · 103
N-[(R,S)-2-Ethylhydrocinnamoyl]glycine
C6H5 NH
COOH
O
3000 ± 250 8.3 ± 0.27 3.5 ± 0.31 · 103
Tiopronin
N
H
COOH
O
SH
33 ± 5.1 0.7c 3 · 104
L-Alanylglycine
N
H
COOH
O
NH2
2400 ± 230 9.8 ± 0.16 5.1 ± 0.50 · 103
N-(Isobutyryl)glycine
N
H
COOH
O
1600 ± 70 9.5 ± 0.14 7.4 ± 0.34 · 103
S-2-Methyltiopronin
N
H
COOH
O
S
460 ± 73 1.2 ± 0.36 3.3 ± 1.4 · 103
aKinetic constants ± S.E. are from computer ﬁts of the initial rate data to Eq. (1).
bThe compounds are grouped into structurally related families.
cAn approximate VMax for thiorphan and tiopronin was calculated using the equation for substrate inhibition (v = VMAX [S]/[KM + [S]+{[S]
2/Ki}])
and the experimentally determined value for v at [S] = 83 lM and KM = Ki,s and Ki = Ki,i.
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from PAM, the extent of inhibition at any given concentration
of tiopronin and thiorphan should match the equilibrium con-centration of the copper Æ inhibitor complex. Sugiura and
Hirayama [44] provide a detailed study of the pH-dependent
interaction of Cu(II) with tiopronin in aqueous solution. These
526 N.R. McIntyre et al. / FEBS Letters 580 (2006) 521–532data enable us to calculate the equilibrium concentrations of
all the forms shown in Fig. 5 under the conditions of our tio-
pronin inhibition experiments. Because similar data does not
exist for thiorphan, we used the pKa and pKassociation values
shown in Fig. 5 to also model our results for the inhibition
of PAM by thiorphan.
At pH 6.0 with a solution containing 1.0 lM Cu(II), 1.1 nM
PAM, and 30–120 lM thiorphan, the predominant thiorphan
form is L1 representing >97% of the [thiorphan]total. The total
[Cu(II)]free, available to bind to copper-free PAM, decreases
from 220 nM at 30 lM thiorphan to 66 nM at 120 lM thior-
phan (Table 2). Information on the dissociation constants for
the binding of Cu(II) to PAM is limited, but the best data indi-
cates that the enzyme has high aﬃnity for the binding of the
ﬁrst Cu(II), Kd  60 nM, while the second Cu(II) binds with
a Kd = 60 nM [46]. Using the Kd values for Cu(II) binding
and the total [Cu(II)]free, we calculate that the ratio of
[PAM Æ 2Cu(II)]/[PAM]total rangesfrom21%at30 lMthiorphan
to 47% at 120 lM thiorphan. The agreement between the exper-
imentally determined ratio of VMAX,inhibitor/VMAX,no inhibitorN
H
COOH
O
SH
N
H
COO
O
SH
pKa = 3.60
N
H
COO
O
S
pKa = 8.74
L
L2
pKassociati
L0
N COO
O
S
pKa ~ 15
L3
Fig. 5. Equilibrium species for thiorphan and tiopronin in the presence of C
and Martin [63].
Table 2
Equilibrium concentrations of the thiorphan species, Cu(II)free,and active PA
[L1]total (lM) ½L1  ðlMÞ ½L21  ðnMÞ [ML1] (lM) ½M
30 29.6 54 0.48 0.3
60 59.0 110 0.54 0.3
90 88.9 160 0.56 0.3
120 118.8 220 0.57 0.3
aThe ligand, L1, is thiorphan.and the calculated ratio [PAM Æ 2Cu(II)]/[PAM]total at diﬀerent
concentrations of thiorphan is high (Table 2). These calcula-
tions strongly suggest that inhibition observed for thiorphan
results from the chelation of Cu(II) by thiorphan; thus, pre-
venting the formation of active PAM Æ 2Cu(II). In other words,
PAM competes ineﬀectively with thiorphan for the binding of
Cu(II) from solution.
Similar analysis of the tiopronin inhibition is complicated by
the diﬀerences in experimental conditions. The inhibition con-
stants for tiopronin inhibition were obtained by measuring the
dependence of the KM,app and VMAX,app for N-acetylglycine
oxidation on [tiopronin]. N-Acetylglycine oxidation was mon-
itored by O2 consumption, a relatively insensitive assay of
PAM activity requiring a high concentration of PAM. Under
these conditions, [Cu(II)]total was 1.0 lM and [PAM]total was
0.23 lMand the depletion of Cu(II) by binding to PAM cannot
be ignored in our calculations. We made the following assump-
tions in order to calculate the values shown in Table 3, (a) the
ﬁrst Cu(II) binds with a suﬃciently low Kd that the [Cu(II)]free
was reduced from 1.0 to 0.77 lM, (b) that [PAM]copper-free isCu(II)
on = -7.6
ML
ML
N
H
COO
O
S
Cu(II)
N COO
O
S
Cu(II)
pKa = 6.2
u(II). The pKa values were from Sugiura and Hirayama [44] and Sigel
M Æ 2Cu(II)a
L1  ðlMÞ [Cu(II)]free (nM) ½PAM2CuðIIÞ½PAMtotal
V MAX; inhibitor
VMAX;no inhibitor
0 220 0.78 0.79
4 120 0.66 0.65
6 90 0.59 0.56
6 70 0.53 0.49
3 Glide score is a measure of the enzyme–substrate interaction energy
(binding aﬃnity) calculated from a molecular mechanics force ﬁeld.
Emodel is a composite scoring function, consisting of the Glide score
calculation and the internal-strain energy of the docked substrate, used
to both select and rank enzyme-bound substrate.
Table 3
Equilibrium concentrations of the tiopronin species, Cu(II)free and active PAMÆ2Cu(II)
a
[L2]total (lM) [L

2 ] (lM) [L
2
2] (nM) [ML2] (lM) [ML2 ] (lM) [Cu(II)]free (nM) PAM2CuðIIÞ½PAMtotal
VMAX; inhibitor
V MAX; no inhibitor
20 19.5 40 0.26 0.16 180 0.75 0.66
40 3.94 70 0.32 0.20 110 0.64 0.49
60 59.3 110 0.34 0.22 80 0.57 0.39
100 99.2 180 0.38 0.24 50 0.46 0.58
aThe ligand, L2, is tiopronin.
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inactive PAM Æ Cu(II) and active PAM Æ 2Cu(II). While the
agreement between the ratio of VMAX,inhibitor/VMAX,no inhibitor
and the calculated ratio [PAM Æ 2Cu(II)]/[PAM]total as a func-
tion of [tiopronin] is not as strong as that seen in Table 2 for
thiorphan, the general trend in the data is correct. Again, the
calculations for tiopronin are consistent with our hypothesis
that the inhibition caused by the thiol-containing N-substituted
glycines is due to the chelation of copper by tiopronin prevent-
ing the formation of active PAM Æ 2Cu(II). The relatively low
VMAX,app values observed for tiopronin and thiorphan as sub-
strates may result from the relatively low levels of active
PAM Æ 2Cu(II) that exist in the presence of these copper-chelat-
ing substrates.
The mixed-type inhibition pattern obtained for tiopronin
and thiorphan provides additional evidence that inhibition
mediated by these compounds results from the extraction of
PAM-bound copper. Both are substrates and, thus, must di-
rectly compete for the same enzyme form as the oxidizable sub-
strate, N-dansyl-Tyr-Val-Gly and N-acetylglycine, generating
the observed increases in the KM,app as a function of inhibitor.
The concentration dependent removal of copper, decreasing the
concentration of active PAM Æ 2Cu(II), would yield an ob-
served decrease in VMAX,app as a function of inhibitor. Meth-
ylation of the thiol would signiﬁcantly reduce the chelation
potential of tiopronin yielding an N-substituted glycine that
we would expect to be a substrate for PAM that is competitive
vs. N-dansyl-Tyr-Val-Gly, exactly what we obtain for S-meth-
ylthiopronin (Table 1 and Fig. 4B). Note that other metal-che-
lating inhibitors have also been shown to be non-competitive
inhibitors against other metalloenzymes [47–49].
3.4. Modeling of thiorphan, tiopronin, and related analogs in the
PHM active site
The X-ray structures of oxidized and reduced PHM, the cat-
alytic unit catalyzing the copper-dependent hydroxylation of
glycine (Fig. 2), reveal that the two bound copper atoms are
separated by 11 A˚ across a solvent-accessible active site cleft
[26,27]. The catalytic roles of the two coppers are diﬀerent;
CuH is involved in electron transfer while CuM is involved in
O2 binding and glycine hydroxylation [21]. The PHM-bound
coppers being named for their respective ligands, CuH having
three His ligands and CuM, two His and one Met ligand [50].
A recent structure of PHM/ce:inf> in a pre-catalytic complex
[27], O2 coordinated to CuM and N-acetyldiiodotyrosyl-D-thre-
onine (a substrate analog) in the active site, provides us with an
excellent opportunity to model the sulfur-containing N-substi-
tuted glycines in the PHM active site to better understand the
relatively high aﬃnity observed for these compounds. These
compounds must bind in the PHM active site because all are
substrates for the enzyme (Table 1).
Three PHM grids were chosen as discussed in the methods:
reduced PHM with two Cu(I) atoms and O2 bound (GRID1),reduced PHM with two bound Cu(I) atoms and no bound O2
(GRID2), and oxidized PHM with two bound Cu(II) atoms
(GRID3). The protonated thiol forms of tiopronin and thior-
phan (L in Fig. 5) and all the analogs included in Table 1 bind
similarly to reduced PHM, with and without bound O2
(GRID1 and GRID2). This means that the ligand orientation
within the active site of reduced PHM, as deﬁned by the Emo-
del and Glide scores 3, are similar for all the compounds in-
cluded in Table 1 (Table 4). The thiolate forms of tiopronin
and thiorphan (L2 in Fig. 5) also bind in a similar orientation,
within GRID1 and GRID2, diﬀering only by a reduction in
the Cu(I)M–S bond distances (Table 4).
While the concentrations of L2 and L3 (the tiopronin and
thiorphan forms with an unprotonated carboxylate, thiolate,
and amide nitrogen, see Fig. 5) are low, 0.2% for L2 and
2 · 108% for L3 of the total [ligand] at pH 6.0, we can
model the interaction of these forms with PHM. We found a
signiﬁcant decrease in the Emodel and Glide scores for the
binding of the L2 and L3 forms of tiopronin and thiorphan
to the oxidized enzyme (GRID3 compared to scores obtained
for GRID1 and GRID2) (Table 4). The decreases in both the
Emodel and Glide scores are indicative of a higher aﬃnity of
the enzyme for the docked ligands. Both the L2 and L3
forms of tiopronin and thiorphan bind strongly to Cu(II)H.
The Emodel and Glides scores for tiopronin and thiorphan de-
crease for L3 relative to L2 directly relating to the increased
coordination of tiopronin and thiorphan from the bi-dentate
metal Æ ligand complex (ML in Fig. 5) to the tri-dentate metal-
ligand complex (ML in Fig. 5). Models for oxidized PHM
with the L3 forms of tiopronin and thiopronin bound at
Cu(II)H are shown in Fig. 6A and B. The high aﬃnity interac-
tion between the L2 and L3 forms of tiopronin and thior-
phan with oxidized PHM compared with both GRID 1 and
2 suggest that the presence of oxygen with the PHM grid does
not aﬀect the binding aﬃnity of tiopronin and thiorphan,
though the oxidation state of the PHM-bound copper appears
to have a large eﬀect on substrate binding aﬃnity. This pro-
vides additional evidence for the coordination of PHM-bound
CuH(II) by the L
2 and L3 states of thiorphan and tiopronin
beyond the chelation of non-enzymatically bound copper.
3.5. Biological relevance
Clinical dosing of acetorphan, the prodrug of thiorphan [2],
at 300 mg leads to a peak plasma concentration of 0.8–1.0 lM
after 1 h, with an elimination half life of 3 h. Patients suﬀering
from cystinuria are given daily doses of 1200 mg of tiopronin
[51]. A 500 mg oral dose of tiopronin yields a maximal plasma
Table 4
Bond distances in the models of the tiopronin, thiorphan, and related analogs in the PHM active sitea
Compound S–CuM (A˚) S
–CuM (A˚) S
–CuH (A˚) Ha– CuM (A˚) Ha–O (A˚) COO
–CuH (A˚) COO
–CuM (A˚) Emodel score Glide score
(A) GRID1 – reduced PHM with O2 bond, PHM Æ 2Cu(I) Æ O2
Thiorphan (L form, –SH and –NH) 4.4 N/A N.A 5.9 4.9 2.4 5.5 73 7.0
Thiorphan (L2 form, –S and –NH) N/A 6.2 2.6 2.8 3.0 2.3 5.8 88 4.6
Thiorphan (L3 form, –S and –N) N/A 3.6 9.8 4.8 3.9 2.9 5.3 99 6.0
Tiopronin (L form, –SH and –NH) 5.8 N/A N/A 3.0 3.1 2.3 5.8 77 6.6
Tiopronin (L2 form, –S and –NH) N/A 3.1 8.5 5.1 5.6 2.2 5.8 60 5.5
Tiopronin (L3 form, –S and –N) N/A 2.9 8.4 3.5 3.5 2.4 5.5 92 5.1
S-Methyltiopronin(–SCH3 and –NH) 5.6 N/A N/A 5.5 5.4 2.3 5.8 65 7.1
N-(R,S)-2-Methylhydrocinnamoyl)glycine N/A N/A N/A 6.1 5.7 2.3 5.8 69 5.9
N-(R,S)-2-Ethylhydrocinnamoyl)glycine N/A N/A N/A 6.1 5.7 2.2 5.8 70 7.4
L-Alanylglycine N/A N/A N/A 6.0 3.6 2.3 5.8 63 6.8
N-(Isobutyryl)glycine N/A N/A N/A 6.0 3.6 2.3 5.7 59 4.9
(B) GRID2 - Reduced PHM (no bound O2), PHM Æ 2Cu(I)
Thiorphan (L form, –SH and –NH) 4.9 N/A N.A 3.9 N/A 5.7 2.3 63 6.1
Thiorphan (L2 form, –S and –NH) N/A 2.6 7.6 5.1 N/A 2.2 5.8 90 6.5
Thiorphan (L3 form, –S and –N) N/A 5.3 7.9 3.0 N/A 5.6 2.3 110 6.1
Tiopronin(L form, –SH and –NH) 5.5 N/A N/A 2.9 N/A 2.3 5.7 60 5.2
Tiopronin (L2 form, –S and –NH) N/A 2.6 7.3 5.4 N/A 2.3 7.0 77 5.3
Tiopronin (L3 form, –S and –N) N/A 4.9 7.4 3.4 N/A 2.4 5.5 95 4.2
S-Methyltiopronin(-SCH3 and –NH) 5.5 N/A N/A 2.3 N/A 2.3 5.7 64 5.5
N-((R,S)-2-Methylhydrocinnamoyl)glycine N/A N/A N/A 4.9 3.6 2.3 2.3 64 6.7
N-((R,S)-2-Ethylhydrocinnamoyl)glycine N/A N/A N/A 5.3 3.8 2.5 2.5 62 6.2
L-Alanylglycine N/A N/A N/A 4.7 5.8 2.3 2.3 65 7.0
N-(Isobutyryl)glycine N/A N/A N/A 5.0 5.7 2.4 2.4 56 5.6
Compound S–CuM (A˚) S
–CuM (A˚) S
–CuH (A˚) Ha– CuM (A˚) Ha–O(A˚) COO
–CuH (A˚) COO
–CuM (A˚) N
–CuH (A˚) Emodel score Glide score
(C) GRID3, Oxidized PHM(no boundO2), PHM Æ 2Cu(II)
b
Thiorphan (L form, –SH and –NH) 5.5 N/A N.A 4.1 N/A 2.1 7.1 N/A 110 7.5
Thiorphan (L2 form, –S and –NH) N/A 2.5 9.1 5.8 N/A 2.2 8.4 N/A 160 7.3
Thiorphan (L3 form, –S and –N) N/A 9.8 2.5 6.2 N/A 2.1 9.2 2.2 240 8.9
Tiopronin (L form, –SH and –NH) 5.7 N/A N/A 9.5 N/A 2.1 8.7 N/A 100 7.1
Tiopronin (L2 form, –S and –NH) N/A 8.5 2.5 7.5 N/A 2.1 9.2 N/A 150 7.2
Tiopronin (L3 form, –S and –N) N/A 9.4 2.6 7.9 N/A 2.3 9.8 2.3 220 8.5
S-Methyltiopronin(–SCH3 and –NH) 7.2 N/A N/A 4.0 N/A 2.1 9.2 N/A 110 7.7
N-(R,S)-2-Methylhydrocinnamoyl)-glycine N/A N/A N/A 4.1 N/A 2.1 9.0 N/A 110 7.4
N-(R,S)-2-Ethylhydrocinnamoyl)-glycine N/A N/A N/A 9.4 N/A 2.1 9.3 N/A 110 8.2
L-Alanylglycine N/A N/A N/A 9.2 N/A 4.3 10.1 N/A 110 7.7
N-(Isobutyryl)glycine N/A N/A N/A 9.3 N/A 2.1 9.2 N/A 110 7.4
aN/A, not applicable.
bThe distance from N to CuH is only included in Table 4C because the L
3 forms of thiorphan and tiopronin whould only coordinate to CuH(II) and not CuH(I). Oxidized Cu(II) is only found in
GRID3.
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Fig. 6. Interaction of the PHM CuH(II) binding pocket with the L
3 form of thiorphan (A) and tiopronin (B). The oxidized PHM Æ ligand models,
active site binding aﬃnity, and bond distances for thiorphan (A) and tiopronin (B) (ball and stick) to were calculated using Glide (Table 4).
Thiorphan and tiopronin are represented as ball and stick models; oxidized PHM as a stick model of the CuH(II) binding pocket containing residues
His-106, His-107, and His-172; and red, oxygen; blue, nitrogen; yellow, sulfur; gray, carbon; and green, CuH(II).
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tial elimination half lives of 2.2 ± 0.4 and 22.6 ± 11.3 h, respec-
tively [52]. Interestingly, PAM has been found to co-localize
with thiorphan in the blood, heart, and brain [1,53–55] whiletiopronin co-localizes with PAM in the blood and the heart
only [53,54,56]. Though, being negatively charged at physio-
logical pH (L in Fig. 5), tiopronin is unlikely to cross the
blood–brain barrier to any signiﬁcant extent. The signiﬁcance
530 N.R. McIntyre et al. / FEBS Letters 580 (2006) 521–532of PAM and thiorphan or tiopronin being found together in
the blood and the heart is unclear because the function of
PAM in these tissues is presently not well understood. The
most intriguing site of co-localization is the brain.
Analgesic studies with mice indicate that the benzyl ester of
acetorphan is readily cleaved in the serum, leaving the metab-
olite S-acetylthiorphan [1,55]. Lambert et al. [55] suggest this
metabolite retains suﬃcient lipophilicity to cross the blood–
brain barrier, distributing thiorphan after thioester hydrolysis
within the brain. With the wide distribution of PAM within the
brain along with its important regulatory role in hormone acti-
vation [21], interaction of an acetorphan metabolite with PAM
seems plausible. Our results suggest that thiorphan inhibits
peptide processing in the brain at two steps, the amidation
reaction catalyzed by PAM and peptide degradation catalyzed
by NEP.
The interaction of PAM with thiorphan and tiopronin ap-
pear to greatly diﬀer. While both compounds interacted with
PAM in vitro (Table 1), the strongest evidence for the potential
inhibition of in vivo amidation appears to be with thiorphan.
Though, the phenotype of this interaction would, theoretically,
be subtle. NEP inhibition would decrease the proteolysis and
hydrolysis of opioid and non-opioid peptides [57]. As amida-
tion has been observed with several enkephalins, thiorphan
inhibition of PAM would be expected to result in the reduction
of amidated enkephalins, proportional to thiorphan absorption
[58]. Therefore, the interplay of both NEP and PAM inhibition
have the potential to disrupt both primary and tertiary meta-
bolic pathways associated with enkephalin processing in vivo.4. Conclusion
In conclusion, we have demonstrated that two sulfur-con-
taining drugs, tiopronin and thiorphan, inhibit PAM with Kd
values <100 lM. These results are of pharmalogical signiﬁ-
cance given the importance of PAM in the biosynthesis of a-
amidated peptide hormones and a potential role in the
in vivo production of oleamide and other bioactive fatty acid
primary amides. The inhibition observed for tiopronin and thi-
orphan most likely results from the decrease in PAM Æ 2Cu(II)
concentration and the coordination of CuH(II), which is essen-
tial for catalysis. These results are valuable as a PAM speciﬁc
inhibitor could prove therapeutically useful for the treatment
of small cell lung cancer or prostate cancer. These cancers
over-express both PAM and growth stimulating a-amidated
peptide hormones [59–62]. The most potent PAM inhibitors
developed to date, N-acylated dipeptides with a C-terminal
homocysteine (IC50 values as low as 8 nM) contain a thiol moi-
ety, which is proposed to interact with the one of the PAM-
bound copper atoms [37]. The work we report here strongly
indicates that the future development of PAM inhibitors of
even higher aﬃnity, Kd values <8 nM, should judiciously
incorporate a thiol to chelate (and possibly remove) the en-
zyme-bound copper atoms.
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